The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

Xiaolei Wei, Meng Xu, Yongqiang Wei, Fen Huang, Tong Zhao, Xiangzhao Li, Ru Feng, B. Hilda Ye

Research output: Contribution to journalArticle

8 Scopus citations


Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

Original languageEnglish (US)
Article number34
JournalJournal of Hematology and Oncology
Issue number1
Publication statusPublished - Apr 16 2014



  • Bone marrow involvement
  • CD44 variant isoforms
  • CHOP
  • Prognosis
  • Rituximab

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Cite this